Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: Journal of Medical Internet Research

Date Submitted: Sep 28, 2020
Date Accepted: Dec 24, 2020
Date Submitted to PubMed: Jan 4, 2021

The final, peer-reviewed published version of this preprint can be found here:

Use of a Remote Oncology Pharmacy Service Platform for Patients With Cancer During the COVID-19 Pandemic: Implementation and User Acceptance Evaluation

Chen ZJ, Liu T, Liang WT, Liu Q, He R, Chen QC, Li QF, Zhang Y, Du XD, Pan Y, Liu S, Li XY, Wei X, Huang H, Huang HB

Use of a Remote Oncology Pharmacy Service Platform for Patients With Cancer During the COVID-19 Pandemic: Implementation and User Acceptance Evaluation

J Med Internet Res 2021;23(1):e24619

DOI: 10.2196/24619

PMID: 33395398

PMCID: 7894743

Implementation of A Remote Oncology Pharmacy Service Platform During the COVID-19 Pandemic: The Sun Yat-sen University Cancer Center Experience

  • Zhuo-Jia Chen; 
  • Tao Liu; 
  • Wei-Ting Liang; 
  • Qing Liu; 
  • Rong He; 
  • Qian-Chao Chen; 
  • Qiu-Feng Li; 
  • Yao Zhang; 
  • Xiao-Dong Du; 
  • Ying Pan; 
  • Shu Liu; 
  • Xiao-Yan Li; 
  • Xue Wei; 
  • He Huang; 
  • Hong-Bing Huang

ABSTRACT

Background:

The outbreak of COVID-19 increased difficulties associated with health management, especially cancer management. To provide continuous pharmaceutical care to cancer patients, the Sun Yat-sen University Cancer Center (SYSUCC) implemented a remote pharmacy service platform based on its already existing online hospital app, known as Cloud SYSUCC.

Objective:

The aim of this study is to investigate the characteristics, acceptance, and initial impact of Cloud SYSUCC during the outbreak of COVID-19 in a tertiary cancer hospital in China.

Methods:

The total number of online prescriptions and detailed information were obtained during the first 6 months after work resumption. Patients’ gender, age, residence, primary diagnosis, drug classification, weekly number of prescriptions, prescribed drugs and patients were included in the analysis. Meanwhile, a telephone survey regarding the patients’ satisfaction using the remote prescription service was conducted.

Results:

A total of 1718 prescriptions including 2022 drugs for 1212 patients were delivered to 24 provinces and municipalities directly under the Central Government of China between February 12, 2020 and August 11, 2020. The majority of patients were female (841, 69.39%) and 90.18% (n=1093) of the patients were aged 31 to 70 years old. The top three online medical prescription diagnosis were breast cancer (599, 49.42%), liver cancer (249, 20.54%), and thyroid cancer (125, 10.31%). Of the 1718 delivered prescriptions, 1435 (83.5%) were sent to Guangdong Province and 283 (16.5%) were sent to other provinces in China. Of the 2022 delivered drugs, 1012 (50.05%) were hormonal drugs. The general trend in the use of the online prescription service was down since the 10th weeks. A telephone survey showed 88% (n=88) participants were very satisfied while 12% (n=12) were somewhat satisfied with our remote pharmacy service platform.

Conclusions:

The Cloud SYSUCC remote pharmacy platform is efficient and convenient for continuous pharmaceutical care to cancer patients during the COVID-19 crisis. The widespread use of this platform can help to reduce person-to-person transmission as well as the infection risk of patients with cancer diseases. Further efforts need to be made to improve the quality and acceptance of Cloud SYSUCC, as well as to regulate and standardize the management of this novel service.


 Citation

Please cite as:

Chen ZJ, Liu T, Liang WT, Liu Q, He R, Chen QC, Li QF, Zhang Y, Du XD, Pan Y, Liu S, Li XY, Wei X, Huang H, Huang HB

Use of a Remote Oncology Pharmacy Service Platform for Patients With Cancer During the COVID-19 Pandemic: Implementation and User Acceptance Evaluation

J Med Internet Res 2021;23(1):e24619

DOI: 10.2196/24619

PMID: 33395398

PMCID: 7894743

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.